30 closest matches · ranked by relevance
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Prostate Cancer
Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Prostate Cancer · Oligometastases
Primary: Progression at 6 Months — 11; 7 Participants
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Lung Cancer · Oligometastatic Lung Tumor
Primary: Feasibility of the ONE STOP Workflow as Measured by the Number of Participants With Successful Completion of the ONE STOP Workflow Through Treatment Delivery — 8…
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Primary: Progression Free Survival (PFS) — 19.1 Months
Neoplasms, Metastatic
Primary: Percentage of Curatively Treated Patients With Progression-free Survival — 16 percentage of participants
Prostate Cancer
Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Oligometastases
Primary: Percentage of Participants With Freedom From Local Progression (FFLP) — 78.4 percentage of participants
Metastatic Malignant Neoplasm to Brain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
Stage IV Prostate Cancer
Primary: Number of Participants With PSA < 0.6 ng/mL — 5 Participants
Prostate Cancer
Primary: Median Duration of Response — NA; NA months
Prostate Cancer
Primary: Efficacy as Assessed by 2-year PSA Progression-free Survival Rate — 17 Participants
Large Brain Mets
Primary: Number of Patients Experiencing DLT — 0; 0; 0; 0 participants
Liver Metastases · Lung Metastases · Recurrent Melanoma
Primary: Rate of Progression-free Survival by mWHO Criteria — 0.75 months
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Brain Cancer · Neoplasm Metastasis · Cancer of Brain and Nervous System
Primary: Stereotactic Radiosurgery (SRS) Maximum-tolerated Dose (MTD) — 0; 0; 0; 0 Dose-limited toxicity (DLT) events
Breast Cancer, Metastatic
Primary: Overall Survival — 74 percentage of participants
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
Malignant Neoplasm Brain
Primary: Local Control Rate (LCR) at 6 Months — 0.817 proportion of patients
Liver Metastases
Primary: Maximum Tolerated Dose (MTD) — 60 Gy
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Prostate Cancer Recurrent
Primary: Participants With Greater Than or Equal to 50% Induction in Serum PAR4 Levels — 11 Participants
Prostate Cancer
Primary: Progression-free Survival — 10.5; 11.8 Months
Brain Metastases
Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy